In the BioHarmony Drug Report Database

"Preview" Icon

Abiraterone

Yonsa, Zytiga (abiraterone) is a small molecule pharmaceutical. Abiraterone was first approved as Yonsa on 2011-04-28. It is used to treat castration-resistant prostatic neoplasms in the USA. It has been approved in Europe to treat prostatic neoplasms. The pharmaceutical is active against steroid 17-alpha-hydroxylase/17,20 lyase. Zytiga’s patents are valid until 2034-05-20 (FDA).

 

Trade Name

 

Zytiga
 

Common Name

 

abiraterone
 

ChEMBL ID

 

CHEMBL254328
 

Indication

 

castration-resistant prostatic neoplasms, prostatic neoplasms
 

Drug Class

 

Antiandrogens

Image (chem structure or protein)

Abiraterone structure rendering